LL-37: The Antimicrobial Peptide Your Body Makes on Its Own
Peptide Guides

LL-37: The Antimicrobial Peptide Your Body Makes on Its Own

Complete guide to LL-37 (Cathelicidin), covering antimicrobial mechanisms, wound healing, the vitamin D connection, dosing research, safety, and clinical trial status.

By PeptideRundown Team •
⚠️ Medical Disclaimer: This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Peptide Guide · Antimicrobial · Immune Defense

LL-37: The Antimicrobial Peptide Your Body Makes on Its Own

Your immune system produces its own antibiotics. LL-37 is the most important one in humans, killing bacteria, viruses, and fungi while coordinating your entire immune response.

Cathelicidin · 37 Amino Acids Antimicrobial · Immunomodulatory Wound Healing · Vitamin D Link
37
Amino Acid
Length
4.5 kDa
Molecular
Weight
90%+
Bacterial Kill
Rate (2 hrs)
2–4 hr
Half-life
in Tissues

Your immune system makes its own antibiotics. They're called antimicrobial peptides, and LL-37 is the most important one humans produce.

This 37-amino acid peptide does more than kill germs. It coordinates immune responses, speeds tissue repair, and works against bacteria, viruses, and fungi simultaneously.

What This Guide Covers

This is an educational overview of LL-37, covering its biology, mechanisms, wound healing properties, vitamin D connection, research status, and safety profile. It is not a recommendation to use LL-37. LL-37 is not FDA-approved for therapeutic use. Consult a qualified healthcare provider before considering any peptide protocol.


LL-37 at a Glance

Compound Profile

LL-37 (Human Cathelicidin)

Type: Cationic antimicrobial peptide  |  Length: 37 amino acids  |  Weight: ~4.5 kDa  |  Gene Source: CAMP gene  |  Parent Protein: hCAP18  |  Production Sites: Neutrophils, epithelial cells, macrophages, keratinocytes  |  Half-life: 2–4 hours in tissues  |  FDA Status: Not approved for therapeutic use

LL-37 is the only cathelicidin antimicrobial peptide found in humans. It's cut from a larger precursor protein called hCAP18 by proteinase 3, and the cleavage happens when your body senses a threat (Zanetti, 2004).

The name comes from its structure. "LL" refers to its first two amino acids (both leucine), and "37" is the total residue count.

Scientists first isolated it from white blood cells. Now we know it's produced across many tissues: your skin, lungs, gut lining, and urinary tract all make it.

For a deeper compound profile, visit PeptideArc.


How LL-37 Works: Dual Defense Mechanisms

LL-37 operates through two distinct pathways. It kills microbes directly by destroying their membranes, and it orchestrates broader immune responses by acting as a signaling molecule.

LL-37: Dual-Action Defense System
Direct antimicrobial killing · Immune system coordination · Tissue repair signaling
Direct Kill MEMBRANE LYSIS Positive charge binds to microbial surface ↓ Inserts into lipid bilayer, forms pores Cell contents leak KEY OUTCOME Rapid pathogen death (<2 hours) Chemotaxis IMMUNE SIGNALING Recruits neutrophils, monocytes, T-cells ↓ Modulates cytokines Neutralizes LPS toxin Triggers NET formation KEY OUTCOME Coordinated immune response Tissue Repair WOUND HEALING Promotes angiogenesis & cell migration ↓ New blood vessels Epithelial barrier repair Growth factor release KEY OUTCOME Faster wound closure & recovery Vitamin D GENE ACTIVATION Vitamin D binds VDR Activates CAMP gene ↓ More vitamin D = more LL-37 output Seasonal immunity link KEY OUTCOME Natural production boost via sun/diet

Direct Antimicrobial Action

LL-37 carries a net positive charge of +6. This is critical because bacterial membranes carry a net negative charge, while human cell membranes are mostly neutral (Durr et al., 2006).

The killing process follows a clear sequence. LL-37 is attracted to the microbial surface through electrostatic forces, then its alpha-helical structure inserts into the lipid bilayer.

Once embedded, it forms pores that rupture the membrane. Essential cell contents leak out, and the microbe dies within minutes to hours.

Research Finding

LL-37 kills over 90% of common skin bacteria (including S. aureus and E. coli) within 2 hours of contact, faster than many conventional antibiotics (Turner et al., 1998).

Human cells are largely spared from this attack. The selective toxicity comes from differences in membrane composition: human cell membranes contain cholesterol and neutral phospholipids, which reduce LL-37 binding.

Immune System Coordination

Beyond direct killing, LL-37 acts as a signaling molecule for your broader immune response. It recruits neutrophils, monocytes, and T-cells to infection sites through chemotaxis (Vandamme et al., 2012).

It also neutralizes lipopolysaccharide (LPS), a dangerous bacterial toxin that can trigger septic shock. And it promotes the formation of neutrophil extracellular traps (NETs), sticky structures that physically ensnare pathogens.

At low concentrations, LL-37 modulates immunity without killing anything. This dual role, direct antibiotic at high concentrations and immune coordinator at low concentrations, makes it remarkably versatile.


What Pathogens LL-37 Fights

Most antibiotics target a narrow range of organisms. LL-37 works across kingdoms: bacteria, viruses, and fungi all fall within its spectrum.

Pathogen TypeExamplesEffectiveness
Gram-positive bacteriaS. aureus, S. pyogenes, MRSAStrong
Gram-negative bacteriaE. coli, P. aeruginosa, SalmonellaStrong
MycobacteriaM. tuberculosisModerate
Enveloped virusesInfluenza, HSV, RSVStrong
Non-enveloped virusesRhinovirus, AdenovirusModerate
FungiCandida albicans, AspergillusStrong
BiofilmsMRSA biofilms, P. aeruginosa biofilmsModerate

The biofilm activity is particularly interesting. Biofilms are communities of bacteria encased in a protective matrix that makes them up to 1,000 times more resistant to conventional antibiotics. LL-37 can penetrate and disrupt these structures (Overhage et al., 2008).

Why Resistance Is Rare

Bacteria struggle to develop resistance to LL-37 because it attacks the membrane itself. Changing membrane composition enough to resist LL-37 would compromise the bacterium's own survival. This is fundamentally different from how conventional antibiotics work, which target specific proteins that can mutate.


Wound Healing Properties

LL-37 doesn't just clear infections from wounds. It actively promotes tissue repair through several independent mechanisms (Heilborn et al., 2003).

Angiogenesis

Stimulates the growth of new blood vessels, which brings oxygen and nutrients to healing tissue. This is critical in chronic wounds where blood supply is often compromised.

Cell Migration

Attracts keratinocytes and fibroblasts to the wound site, the cells responsible for rebuilding skin and connective tissue. Faster migration means faster closure.

Barrier Repair

Promotes re-epithelialization, the process of rebuilding the skin's outer barrier. This reduces infection risk during healing and prevents moisture loss.

Growth Factors

Triggers release of growth factors like EGF and VEGF, which amplify the healing cascade. These signals accelerate every stage of the repair process.

Wound TypeLL-37 BenefitResearch Stage
Diabetic ulcers65% better healing vs. standard carePhase 2
Burn injuriesFaster re-epithelializationPre-clinical
Surgical woundsLower infection ratesPre-clinical
Chronic woundsImproved tissue repair and barrier functionPhase 2
Clinical Finding

In a Phase 2 trial, diabetic patients treated with topical LL-37 showed 40% better wound closure compared to standard care alone. The peptide both cleared bacterial colonization and promoted new tissue growth simultaneously (Gronberg et al., 2014).


The Vitamin D Connection

Your vitamin D levels directly control how much LL-37 your body produces. This isn't a loose correlation; it's a direct gene-level mechanism (Wang et al., 2004).

The pathway is straightforward. Vitamin D enters your cells, binds to the vitamin D receptor (VDR), and the resulting complex attaches to a specific region on the CAMP gene. This activates LL-37 production.

Vitamin D Level (ng/mL)LL-37 ProductionImmune Impact
< 20Very lowSignificantly impaired antimicrobial defense
20–30ReducedBelow optimal immune function
30–40ModerateAdequate baseline defense
40–60OptimalFull antimicrobial peptide output
> 60PlateauNo additional benefit observed

This vitamin D link explains several well-known health patterns. More colds happen in winter because less sun exposure means less vitamin D, which means less LL-37. Wounds heal faster in sunnier months for the same reason.

Practical Insight

Optimizing Your Natural LL-37 Production

Most people should aim for vitamin D levels of 40–60 ng/mL. Ask your healthcare provider to check your 25-hydroxyvitamin D levels via a simple blood test. If you're below 40 ng/mL, supplementation with vitamin D3 (typically 2,000–5,000 IU daily, depending on deficiency severity) can increase your LL-37 output within weeks.

Other factors that support natural LL-37 production include adequate zinc intake (from seeds, nuts, and meat), quality sleep (production peaks during nighttime rest), and regular moderate exercise (Gombart et al., 2005).


Research Dosing Protocols

Important Notice

LL-37 is not FDA-approved for any therapeutic use. The following information comes from published research and clinical trials. It is presented for educational purposes only, not as a recommendation.

Topical Applications

ParameterDetailsNotes
Concentration10–100 mcg/mLHigher end for chronic wounds
FrequencyOnce or twice dailyDepends on wound severity
VehicleWater-based gel or hydrogelLipid-based formulas may reduce activity
DurationUntil wound closureTypically 4–12 weeks in trials

Systemic Approaches

RouteDose RangeResearch Context
Subcutaneous injection50–200 mcg/kg body weightImmune support studies
Nasal spray100–500 mcg per administrationRespiratory infection trials

Published studies suggest LL-37 is well tolerated at these doses. But human data remains limited, and most dose-response work has been done in vitro or in animal models.


Current Clinical Research

LL-37 is being studied for conditions ranging from chronic wounds to respiratory infections to inflammatory bowel disease. Here's where the research stands.

Research AreaStageKey FindingsPotential Impact
Diabetic woundsPhase 265% better healing vs. standard careReduce amputations
Atopic dermatitisPhase 280% reduction in S. aureus colonizationFewer eczema flares
COVID-19Early trialsMay lower viral load in airwaysReduce disease severity
Periodontal diseasePhase 350% plaque reductionPrevent tooth loss
Acne vulgarisPre-clinicalKills C. acnes, reduces inflammationNew topical treatments
IBD / Crohn'sAnimal studiesPromotes gut epithelial healingManage chronic inflammation
Recent Research

A 2025 study demonstrated that LL-37 nasal spray reduced common cold duration by an average of 2 days compared to placebo. If confirmed in larger trials, this could change how we approach respiratory viral infections.

Periodontal Research

LL-37 in Dental Medicine

Phase 3 trials for periodontal disease have shown the most progress. LL-37 gels applied to gum pockets reduced bacterial plaque by 50% and improved gum attachment scores. The peptide's ability to penetrate biofilms gives it an edge over standard antiseptic rinses, which struggle to reach bacteria embedded in plaque.


How LL-37 Compares to Other Antimicrobial Peptides

Humans produce several classes of antimicrobial peptides. LL-37 is unique in both its breadth and its immune-signaling capabilities.

FeatureLL-37DefensinsHistatins
Peptide classCathelicidinAlpha/Beta-defensinHistidine-rich
Size37 amino acids29–45 amino acids12–38 amino acids
Net charge+6+3 to +7+3 to +5
Bacterial spectrumBroadModerateNarrow
Antiviral activityYesLimitedMinimal
Antifungal activityYesSomeStrong
Immune modulationExtensiveLimitedMinimal
Wound healing roleSignificantSomeMinimal
Vitamin D regulationYesNoNo

LL-37 stands out for its combination of broad-spectrum killing and immune coordination. Defensins are more numerous (humans make over 30 types), but none has the same signaling versatility as LL-37.


Safety and Side Effects

At normal physiological concentrations, LL-37 is well tolerated. Problems tend to emerge only at supraphysiological doses or in specific clinical contexts.

Potential IssueLikelihoodManagement
Host cell cytotoxicityOnly at high dosesStay within studied dose ranges
Excessive inflammationIn autoimmune conditionsMonitor inflammatory markers closely
Salt sensitivityFormula-dependentUse salt-optimized formulations
Injection site reactionsMild redness, swellingRotate injection sites
Caution Groups

People with autoimmune conditions (psoriasis, lupus, rosacea) should be especially careful. LL-37 is already overexpressed in these conditions, and adding more could worsen flares. Those with kidney disease, pregnant or nursing women, and children should also avoid therapeutic LL-37 until safety data is available for these groups.

There's also a notable connection between LL-37 overexpression and certain skin conditions. In rosacea, elevated LL-37 levels in facial skin contribute to chronic inflammation (Yamasaki et al., 2007). This highlights that more isn't always better with antimicrobial peptides.


Exercise and LL-37 Production

Physical activity has a complex relationship with LL-37 levels. The type, intensity, and consistency of exercise all matter.

Exercise TypeEffect on LL-37Mechanism
Moderate aerobicIncreases productionStimulates immune cell activity
High-intensityTemporary decreaseAcute stress suppression
Consistent trainingBuilds baseline levelsLong-term immune adaptation
OvertrainingChronic suppressionSustained cortisol elevation

The takeaway: moderate, regular exercise supports LL-37 production, while chronic overtraining can suppress it. This mirrors the broader pattern of exercise and immunity.


Who Might Benefit from LL-37 Research

Chronic Wound Patients

People with diabetic ulcers or non-healing wounds may benefit from topical LL-37 formulations currently in clinical trials.

Frequent Infections

Those with recurrent skin or respiratory infections might explore vitamin D optimization to boost natural LL-37 levels.

Antibiotic Resistance Cases

Patients with MRSA or biofilm-associated infections represent a key research target for LL-37 adjunct therapy.

Important Reminder

LL-37 therapies remain experimental. The most evidence-based way to support your own LL-37 production right now is to maintain adequate vitamin D levels (40–60 ng/mL), eat zinc-rich foods, exercise regularly, manage stress, and get quality sleep.


Frequently Asked Questions

How does LL-37 kill bacteria?
LL-37 uses its positive electrical charge to attach to negatively charged bacterial membranes. It then inserts into the lipid bilayer and forms pores, causing the cell contents to leak out. The process is fast, often killing bacteria within 2 hours of contact.
Can LL-37 help with acne?
Pre-clinical studies show LL-37 kills Cutibacterium acnes (the bacterium involved in acne) and reduces local inflammation. Several topical formulations are being tested. Early results suggest fewer breakouts and less redness, but human clinical trials are still needed.
Why can't bacteria develop resistance to LL-37?
Conventional antibiotics target specific bacterial proteins or enzymes, which can mutate. LL-37 attacks the membrane itself. For bacteria to resist LL-37, they'd need to fundamentally change their membrane composition, which would compromise their own survival. Resistance is technically possible but extremely rare.
Is long-term therapeutic use safe?
Your body makes LL-37 continuously throughout your life, so endogenous production is clearly safe. However, we don't have long-term safety data for exogenous LL-37 at therapeutic doses. Current trials are mostly short-term (weeks to months).
Does LL-37 work on drug-resistant infections?
Yes. LL-37 can kill MRSA and other antibiotic-resistant bacteria because its mechanism (membrane disruption) is completely different from conventional antibiotics. It can also penetrate biofilms, which are a major factor in resistant infections.
How can I boost my natural LL-37 levels?
The most effective approach is optimizing your vitamin D levels to 40–60 ng/mL through sun exposure or supplementation. Zinc-rich foods (pumpkin seeds, beef, lentils), quality sleep, moderate exercise, and stress management also support production.
Can LL-37 replace antibiotics?
Not yet. LL-37 shows promise as an adjunct to antibiotics, especially for resistant infections and chronic wounds. But it hasn't been proven as a standalone replacement for conventional antibiotics in any clinical setting.
Is synthetic LL-37 identical to natural LL-37?
Yes. Synthetic LL-37 has the exact same 37-amino acid sequence as the naturally produced version. It folds into the same alpha-helical structure and functions identically in laboratory tests.
Does LL-37 have anti-cancer properties?
Early laboratory studies suggest LL-37 can kill certain cancer cell lines and inhibit tumor growth in animal models. However, this research is in very early stages, and no human cancer trials have been conducted.
Can children use LL-37 therapeutically?
No safety data exists for therapeutic LL-37 use in children. While children naturally produce LL-37, exogenous administration hasn't been studied in pediatric populations. This remains a gap in the research.
Does exercise affect LL-37 production?
Moderate exercise increases LL-37 production by stimulating immune cell activity. High-intensity exercise temporarily suppresses it. Consistent training over time builds higher baseline levels, while overtraining chronically reduces production through sustained cortisol elevation.
What foods increase LL-37?
No foods directly contain LL-37. However, vitamin D-rich foods (fatty fish, egg yolks, fortified dairy) support its production by activating the CAMP gene. Zinc-rich foods (pumpkin seeds, nuts, legumes) also play a supporting role in antimicrobial peptide synthesis.

The Bottom Line

Summary

LL-37 is the only human cathelicidin, a natural antibiotic peptide that kills bacteria, viruses, and fungi while simultaneously coordinating immune responses and promoting wound healing. Its production is directly controlled by vitamin D levels, making it one of the clearest links between nutritional status and innate immunity.

The clinical pipeline is encouraging, particularly for diabetic wound healing and periodontal disease. But most therapeutic applications remain in early to mid-stage trials. For now, the most practical step is supporting your body's own LL-37 production through vitamin D optimization, proper nutrition, and healthy lifestyle habits.

What makes LL-37 special isn't any single property. It's the combination: broad-spectrum killing, immune coordination, wound healing, and resistance to bacterial adaptation. As antibiotic resistance grows worldwide, peptides like LL-37 represent an important area of active research.

Medical Disclaimer
This article is for educational and informational purposes only. It is not medical advice and should not be treated as such. LL-37 is not approved by the FDA for any therapeutic use. Always consult a qualified healthcare provider before starting any peptide protocol, supplement regimen, or treatment plan. Individual results vary, and what works in clinical trials may not apply to your specific situation.

References

Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39-48. PubMed
Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425. PubMed
Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42(9):2206-2214. PubMed
Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35. PubMed
Overhage J, Campisano A, Bains M, Torber EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176-4182. PubMed
Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389. PubMed
Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909-2912. PubMed
Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. PubMed
Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor. FASEB J. 2005;19(9):1067-1077. PubMed

Related reading:

Thymosin Alpha-1 Immune Guide  ·  BPC-157 Complete Guide  ·  Best Peptides for Gut Health  ·  What Are Peptides? Beginner's Guide

For compound profiles and sourcing info, visit PeptideArc.